Menu
THERAVIA is a leading international pharmaceutical company specializing in rare or neglected diseases. Formed through the merger of Addmedica and CTRS, we are dedicated to address the unmet medical needs of patients with these challenging conditions. With a deep understanding of the unique challenges faced by individuals affected by rare diseases, we bring together the expertise and resources of Addmedica and CTRS to pioneer innovative therapies. Our mission is to make a tangible difference in the lives of patients, offering them hope and improved quality of life.
At THERAVIA, we foster a culture of scientific excellence, driving collaboration among leading experts to pursue groundbreaking research and development. Our focus on rare or neglected diseases allows us to channel our efforts into areas of critical need, providing patients with much-needed options and renewed hope. Beyond our dedication to develop novel therapeutics, we actively engage with patient communities, advocacy groups, and healthcare professionals to ensure our efforts align with real-world needs. Upholding the highest standards of ethics, compliance, and patient safety, we strive to transform the landscape of rare diseases and make a positive impact.
At THERAVIA, our mission is to bring life to hope by transforming the lives of patients affected by rare or neglected diseases. We are dedicated to advancing innovative solutions that address the unmet medical needs of these individuals, offering them hope, improved outcomes, and an enhanced quality of life.
Developing Innovative Therapies: We prioritize the discovery and development of novel therapies specifically tailored to rare or neglected diseases. Through cutting-edge research and collaboration with leading experts, we strive to bring forth groundbreaking treatments that target the underlying causes of these conditions.
Collaboration and Partnerships: We believe in the power of collaboration to drive progress. We actively seek partnerships with academic institutions, research organizations, and other pharmaceutical companies to leverage collective expertise and resources. By working together, we can accelerate the development and delivery of innovative therapies to those who need them most.
Education and Awareness: We recognize the importance of raising awareness about rare or neglected diseases, both within the medical community and society as a whole. Through educational initiatives and advocacy campaigns, we strive to increase understanding, reduce stigmas, and promote early diagnosis and access to appropriate treatments.
Ethical and Responsible Practices: Patient safety, regulatory compliance, and ethical practices are of utmost importance to us. We adhere to stringent standards and guidelines to ensure that our therapies meet the highest levels of safety, efficacy, and quality. We are committed to transparency, integrity, and accountability in all aspects of our work.
A diverse team of passionate scientists, researchers, and medical professionals.
Deep expertise in rare diseases, neglected conditions, and orphan drug development.
Strategic alliances with academia, research institutions, and non-profit organisations
Fruitful collaboration with patient advocacy groups, key opinion leaders and organisations.
Identification and characterization of rare disease targets.
Development of novel therapeutic approaches.
Early market access programs in France and internationally
Addressing the healthcare needs of underserved populations.
Developing affordable and accessible treatments.
Advocating for equitable access to healthcare resources.
16 rue Montrosier 92200 Neuilly-sur-Seine, France – Tel: +33(0)172 69 01 86
© Copyright 2023 | All Rights Reserved | Last update: 08/2023 | TH-THE01EN
